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Abstract
Background Sarcopenia might function as an indicator for frailty, and as such as a risk factor for the development of
postoperative complications. The aim of this study was to meta-analyse the relation between preoperative sarcopenia and
the development of severe postoperative complications in patients undergoing oncological surgery.
Methods PubMed and Embase databases were systematically searched from inception until May 2018. Included were stud-
ies reporting on the incidence of severe postoperative complications and radiologically determined preoperative sarcopenia.
Studies reporting the skeletal muscle as a continuous variable only were excluded. Data were extracted independently by
two reviewers. Random effect meta-analyses were applied to estimate the pooled odds ratio (OR) with 95% confidence
intervals (95% CI) for severe postoperative complications, defined as Clavien-Dindo grade ≥3, including 30-day mortality.
Heterogeneity was evaluated with I2 testing. Analyses were performed overall and stratified by measurement method, tumour
location and publication date.
Results A total of 1924 citations were identified, and 53 studies (14 295 patients) were included in the meta-analysis. When
measuring the total skeletal muscle area, 43% of the patients were sarcopenic, versus 33% when measuring the psoas area.
Severe postoperative complications were present in 20%, and 30-day mortality was 3%. Preoperative sarcopenia was associ-
ated with an increased risk of severe postoperative complications (ORpooled: 1.44, 95% CI: 1.24–16.8, P<0.001, I
2=55%) and
30-day mortality (ORpooled: 2.15, 95% CI: 1.46–3.17, P<0.001, I
2=14%). A low psoas mass was a stronger predictor for severe
postoperative complications compared with a low total skeletal muscle mass (ORpooled: 2.06, 95% CI: 1.37–3.09, ORpooled: 1.32,
95% CI: 1.14–1.53, respectively) and 30-day mortality [ORpooled: 6.17 (95% CI: 2.71–14.08, ORpooled: 1.80 (95% CI: 1.24–2.62),
respectively]. The effect was independent of tumour location and publication date.
Conclusions The presence of low psoas mass prior to surgery, as an indicator for sarcopenia, is a common phenomenon and
is a strong predictor for the development of postoperative complications. The presence of low total skeletal muscle mass,
which is even more frequent, is a less informative predictor for postoperative complications and 30-day mortality. The low
heterogeneity indicates that the finding is consistent over studies. Nevertheless, the value of sarcopenia relative to other
assessments such as frailty screening is not clear. Research is needed in order to determine the place of sarcopenia in future
preoperative risk stratification.
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Introduction
Surgery is part of the multimodality treatment of most solid
tumours. Though very effective, surgical treatment may lead
to postoperative complications.1,2 Especially in frail patients,
these complications can lead to permanent functional loss
and negatively influence survival and long-term quality of
life.3,4 The benefits of surgery should therefore be carefully
weighed against these negative sequelae.5,6 For this purpose,
there has been increasing attention for methods to identify
frail patients in recent years.4 In some cases, the presence
of factors associated with frailty may lead to the decision
not to perform a certain surgical procedure. In other cases,
interventions may be undertaken to improve a patient’s
performance preoperatively in order to undergo surgery
under the most optimal circumstances.
The presence of preoperative sarcopenia can be a possi-
ble method for detecting frail patients. Sarcopenia describes
the loss of skeletal muscle mass associated with increased
age, so called primary sarcopenia, or secondary to systemic
conditions such as cancer or an inflammatory state.7,8. The
advantage of the use of sarcopenia over other screening
methods for frailty, such as extensive questionnaires and as-
sessments, is its objective, quantitative and relatively quick
nature. Furthermore, the presence of sarcopenia can be de-
termined on images routinely obtained in the oncological
workup, and does therefore not require additional testing
of the patient. Sarcopenia can be diagnosed with the use
of clinical tests and/or measurement of the skeletal muscle
mass.8 A common method for the detection of sarcopenia
is the CT-based estimation of the lean skeletal muscle
mass.9,10
Both a negative and a positive effect of the presence of
sarcopenia on the development of severe complications have
been reported. 11–18 Therefore, we performed a systematic
review and meta-analysis of all the studies that recorded inci-
dences of severe postoperative complications in patients with
or without sarcopenia, undergoing oncological surgery for
any type of solid tumour.
Methods
Search strategy
The Preferred Reporting Items for Systematic Review and
Meta-analysis (PRISMA) and the Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) guidelines were
followed in this systematic review and meta-analysis.19,20
We searched the PubMed and Embase databases for
studies reporting on sarcopenia and postoperative complica-
tions published form the inception of each database to May
1, 2018. The search terms were ‘sarcopenia’, ‘postoperative
complications’, ‘neoplasms’, and ‘surgery’, with synonyms
for each (see Supplementary File S1 for search strategy). No
filters or restrictions were applied.
Selection criteria
The following studies were included: Studies should report
on the development of severe postoperative complications
in the first 30 days after surgery in adult patients. Patients
had to undergo surgical resection of any type of malignancy.
Only studies were included that applied a CT-based assess-
ment of skeletal muscle mass with use of the skeletal
muscle area (SMI) and psoas area (TPI) on the level of the
third lumbar vertebra. Furthermore, only studies were in-
cluded when the presence or absence of sarcopenia was
based on a clearly defined cut-off. Studies were excluded
when skeletal muscle mass was reported as a continuous
variable. Studies describing only a specific type of postoper-
ative complication or studies that did not distinguish severe
complications from less severe or overall complications were
excluded. Non-English studies were excluded. When differ-
ent publications described the same set of patients, the
most recent study was included in the here presented
meta-analysis.
Endpoints
The primary endpoint was the presence of severe
postoperative complications within the first 30 days after
surgery. Severe complications were classified with use of
the Clavien-Dindo scale; complications with score of ≥3
were considered severe postoperative complications.21 The
30-day mortality was considered separately. Data about
the 30-day mortality was obtained in two different ways:
firstly, as the 30-day mortality apart from the severe com-
plications in studies that reported them separately and sec-
ondly, as a grade V complication on the Clavien-Dindo
scale, being a subgroup of the total number of postopera-
tive complications. Therefore, in the latter studies, the
data about patients with grade V complications were used
in both the analysis regarding the severe postoperative
complications and in the analysis regarding the 30-day
mortality.
Data extraction and quality assessment
The first author, year of publication, total study population,
median age, gender, location of the malignancy, number of
patients with and without sarcopenia and the number of pa-
tients with postoperative complications was extracted from
each study.
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We assessed the methodological quality of the included
studies using the Newcastle-Ottawa scale for cohort stud-
ies.22 This scale assesses the patient selection, comparability
and outcomes. The outcomes of the assessments were con-
verted in order to classify each study as having a good, fair
or poor methodological quality. Two reviewers (L. W. and A.
H.) independently performed the process of study selection,
data extraction and quality assessment. Disagreements were
resolved by consensus.
Statistical analysis
For each study. we calculated odds ratios (ORs) and 95%
confidence intervals (95% CI) for postoperative complica-
tions in patients with and without preoperative sarcopenia.
A random-effect model was used for all analyses as we
expected considerable variation in types of cancer and cut-
off values for the definition of sarcopenia. Heterogeneity
was assessed with use of the I2 statistics and was
interpreted as follows: 0–40% low heterogeneity, 30–60%
moderate heterogeneity, 50–90% substantial heterogeneity
and 75–100% considerable heterogeneity.23 To explore
sources of heterogeneity, we performed subgroup analysis
with studies stratified by: measurement method of
sarcopenia (total skeletal muscle mass versus psoas mass),
tumour location and publication date. The stratification
was performed for both severe postoperative complications
and 30-day mortality separately. We only included strata
considering two or more studies. The null hypothesis, that
the relationship between sarcopenia and postoperative
complications or 30-day mortality is equal across the
defined strata, was tested with a X2 test. All analyses were
performed with use of Review Manager (RevMan) 5.3.




A total of 1924 articles was identified by our search. A total of
140 studies met the eligibility criteria and of those studies 53
were included in the meta-analysis (Figure 1). Cross reference
search did not provide additional studies.
Quality of the included studies
A summary of the methodological quality of the included
studies is presented in Table 1. A total of 20 studies (38%)
did have a good methodological quality. In the remaining 33
studies (62%), the methodological quality was poor, due to
a low score on the comparability domain.
Study characteristics
The included studies concerned 14 295 patients. The most re-
ported tumour location was hepatiopancreaticobiliary (22/53
studies), followed by upper gastro intestinal (GI) (12/53
studies), and lower GI (12/53 studies). The estimated pooled
median age of the included studies was 61 years. A total of 25
(47%) studies reported a median age ≥65 years. The majority
of the patients, 78%, in the included studies was male. Half
(26/53) of the included studies were published before 2017
and 27 studies in 2017 and 2018. Characteristics of the
included studies are displayed in Table 2.
Sarcopenia
In 40/53 studies (75%), the total skeletal muscle mass was
used to determine sarcopenia. The psoas mass was used in
13/53 (25%) of the studies. The cut-off values used to deter-
mine low total skeletal muscle mass and low psoas mass,
respectively, are listed in Table S1, ranging from 40.5 to
71.6 in male patients and 33.5 to 55.3 in female patients
for low total skeletal mass and ranging 4.3–7.8 in males and
3.8–6.4 in females for low psoas mass. A total of 5938
patients (42%) were sarcopenic. In studies using the total
skeletal muscle mass, a total of 4849 patients (43%) were
considered sarcopenic, versus 1089 patients (33%) in studies
measuring the psoas area.
Severe postoperative complications
A total of 2920 patients (20%) with severe postoperative
complications were recorded. A total of 1398 patients with
sarcopenia (24%) and 1522 patients without sarcopenia
(18%) developed a severe postoperative complication (see
Figure 2). ORpooled: 1.44 (95% CI 1.24–16.8, P<0.001).
The I2 was 55%, representing moderate heterogeneity. The
outcomes of the analysis did not change when only studies
with good methodological quality were included in the analy-
sis (Figure S1). Subgroup analysis on the effect of the use of
total skeletal muscle mass or psoas mass showed a significant
difference between the subgroups (P 0.04). The pooled OR
for the effect of the presence of sarcopenia on the develop-
ment of severe postoperative complications was 1.32 (95%
CI 1.14–1.53) in studies using total skeletal muscle mass and
2.06 (95% CI 1.37–3.09) in studies using the psoas mass
(Figure 3a). Subgroup analysis based on tumour location or
date of publication showed no differences between the sub-
groups. (Figures S2 and S3).
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Thirty-day mortality
A number of 25 studies with a total of 6411 patients reported
on 30-day mortality. Sarcopenia was present in 46% of the
patients, and the pooled 30-day mortality was 3%. In patients
with sarcopenia, 30-day mortality was 4% and in patients
without sarcopenia 2% [ORpooled: 2.15 (95% CI 1.46–3.17,
P<0.001)] (Figure 4). The I2 was 14%, indicating little
heterogeneity.
Subgroup analysis for the effect of the use of the total
skeletal muscle mass or the psoas mass for the detection of
sarcopenia showed a significant difference between the
subgroups. The pooled OR for the effect of sarcopenia on
the 30-day mortality in studies using the total skeletal muscle
mass was 1.80 (95% CI 1.24–2.62) versus 6.17 (95% CI 2.71–
14.08) in studies using the psoas mass, P<0.001 (Figure 3b).
The subgroup analyses on the effect of tumour location
and date of publication showed no significant differences be-
tween the subgroups. Subgroup analyses are presented in
Figures S2 and S3.
Discussion
In this meta-analysis 14 295 surgical oncological patients
were included from 53 studies, where 20/53 were good qual-
ity studies. Results did not change when only good quality
studies were included. Most studies (22/53) concerned
patients diagnosed with a hepaticopancreaticobiliary malig-
nancy. The prevalence of radiologically determined
sarcopenia is relatively high, with a prevalence of 43% when
sarcopenia was based on total skeletal mass and 33% for
sarcopenia based on psoas mass. Preoperative sarcopenia
was associated with an increased risk of severe postoperative
complications (ORpooled: 1.44, 95% CI: 1.24–16.8, P<0.001,
I2=55%) and 30-day mortality (ORpooled: 2.15, 95% CI:
1.46–3.17, P<0.001, I2=14%). A low psoas mass was a stron-
ger predictor for severe postoperative complications
(ORpooled: 2.06, 95% CI: 1.37–3.09, ORpooled: 1.32, 95% CI:
1.14–1.53, respectively) and 30-day mortality compared with
a low total skeletal muscle mass [ORpooled: 6.17 (95% CI:
2.71–14.08), ORpooled: 1.80 (95% CI: 1.24-2.62), respectively].
Figure 1 Flowchart of included studies
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Table 1 Methodological quality of the included studies with regard to our study question
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The effect on the risk of severe complications was indepen-
dent of tumour location and publication date.
Our analysis showed that the presence of low psoas mass
prior to surgery is a stronger predictor for the development
of postoperative complications when compared with the
presence of low total skeletal muscle mass. This finding has
not been reported earlier. This makes the measurement of
the psoas mass a more adequate risk factor than the mea-
surement of the total skeletal muscle mass in the selection
of patients with an increased risk of developing postoperative
complications. A possible explanation for the greater effect of
a low total psoas mass compared with a low total skeletal
muscle mass might be that the quantification of the psoas
muscles reflects the physical condition of a patient better
than the total skeletal muscle area. The relation between a
low psoas mass and a decreased physical performance has
been discussed in literature.74,75 The psoas muscles are only
active during standing, bending, and lifting, representing an
active lifestyle.76 A decreased psoas mass could therefore in-
dicate that the patient is less active, has a decreased physical
condition, and might subsequently be more frail and vulnera-
ble for the development of postoperative complications.
Furthermore, when a postoperative complication does occur,
the impact of the complication could possibly be less well
compensated, which can lead to a higher mortality risk in
the postoperative period. Another aspect is that low psoas
mass is also related to longer term postoperative mortality
among different groups of patients.24,77,78 Thus suggesting
that low psoas mass might not only reflect a decreased phys-
ical condition on the short term but also represent physical
changes with effects lasting over time.
The use of radiologically determined sarcopenia in preop-
erative risk stratification has some restrictions. Radiologically
assessed sarcopenia is present in a large number of patients.
When measured with total skeletal muscle mass, sarcopenia
is present in almost half of the study population, and when
Table 1 (continued)





















aStudies were considered of good quality on the comparability domain if either selected cohorts or a multivariate analysis on the effect of
sarcopenia on the development of postoperative complications were present.
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measured with psoas mass in one-third of the patients. The
lower prevalence of the low psoas mass emphasizes its better
suitability over the total skeletal muscle mass to select those
patients that are at an increased risk for the development of
postoperative complications. The widespread presence of
sarcopenia reduces its discriminative value between those
at an increased risk and those not at an increased risk for
the development of postoperative complications. In addition,
Table 2 Characteristics of included studies





N % N %
Amini, 201524 763 67 (58–74) 418 55 HPB TPI 192 25.1
Banaste, 201716 214 59 (24–78) 105 49 Lower GI SMI 90 42.1
Chemama, 201625 97 53 (46–62) 37 38 Lower GI SMI 39 40.0
Choi, 201826 180 64 ± 9 98 54 HPB SMI 60 33.3
Coelen, 201527 100 62 ±9 64 64 HPB SMI 42 42.0
Elliot, 201728 192 62 ± 9 156 81 Upper GI SMI 49 25.5
Grotenhuis, 201629 120 62 (19–78) 88 73 Upper GI SMI 54 45.0
Harada, 201530 256 NRc 234d 92 Upper GI TPI 84 32.8
Harimoto, 201331 186 67 ± 11 NR NR HPB SMI 75 40.3
Higashi, 201532 144 65 ± 10 108 75 HPB SMI 72 50.0
Jarvinen, 201833 115 63 ±9 86 75 Upper GI SMI 92 80.0
Jones, 201534 100 69 ±10 60 60 Lower GI TPI 15 15.0
Kudou, 201735 148 NR NR NR Upper GI SMI 42 28.4
Kuwada, 201836 491 ~71e 348 71 Upper GI SMI 123 25.1
Levolger, 201537 90 62 (22–86) 63 70 HPB SMI 52 57.8
Lodewick, 201538 171 64 (24–86) 104 61 HPB SMI 80 46.8
Malietzis, 201639 805 69 (961–77) 472 59 Lower GI SMI 485 60.2
Mason, 201740 698 62 ±7 698 100 Urogenital SMI 388 55.6
Mayr, 201841 327 70 (63–75) 262 80 Urogenital SMI 108 33.0
Nakamura, 201842 328 71 (38–87) 195 59 Other TPI 183 55.8
Nakashima, 201843 341 NR 289 85 Upper GI SMI 171 50.1
Nakanishi, 201844 494 66 ± 12 298 60 Lower GI SMI 298 60.3
Nimomiya, 201745 265 65 ± 10 164 62 HPB SMI 170 64.2
Nishida, 201646 266 69 (27-87) 181 68 HPB SMI 132 49.6
Nishigori, 201647 199 ~65e 164 82 Upper GI SMI 149 74.8
Okumura, 2016 48 207 ~67e 111 54 HPB TPI 71 32.4
Okumura, 2015a49 230 67 (32–87) 124 54 HPB TPI 64 32.1
Okumura, 2015b50 109 68 (63–74) 67 62 HPB SMI 69 63.3
Otsuji, 201551 256 67 (34–85) 162 63 HPB TPI 85 33.2
Ouchi, 201652 60 69 (43–88) 35 58 Lower GI TPI 20 33.3
Pędziwiatr, 201618 124 66 (range NR) 73 59 Lower GI SMI 34 27.4
Peng, 201153 259 58 ± 12 155 60 HPB TPI 41 15.8
Peyton, 201654 128 63 (31–85) 85 66 Urogenital TPI 32 25.0
Rutten, 201755 216 63 (16–85) 0 0 Urogenital SMI 70 32.4
Saeki, 201856 157 65 (range NR) 122 78 Upper GI SMI 85 54.1
Sakurai, 201715 569 67 ± 11 396 70 Upper GI SMI 142 24.9
Da Silva, 201857 250 NR 0 0 Urogenital SMI 56 22.4
Smith, 201458 200 66 ± 12 141 71 Urogenital TPI 77 38.5
Sui, 201759 354 70 ± 11 203 57 HPB SMI 87 24.6
Takagi, 2016 60 254 66 ± 11 207 82 HPB SMI 118 46.5
Takagi, 2017a61 154 65 ± 13 90 58 HPB SMI 38 24.7
Takagi, 2017b62 219 66 ±12 143 65 HPB SMI 55 25.1
Takeda, 201863 144 ~61e 102 71 Lower GI SMI 37 25.7
Tegels, 201564 152 70 (37–88) 87 57 Upper GI SMI 86 56.6
Umetsu, 201865 65 72 (31–81) 47 72 HPB TPI 48 73.8
Valero, 201566 96 62 ± 12 59 61 HPB TPI 47 49.0
Van der Kroft, 201867 63 NR 39 64 Lower GI SMI 33 52.4
Van Vught, 201568 206 ~61e 100 49 Lower GI SMI 90 43.7
Van Vught, 201769 452 65 (58–71) 278 62 Lower GI SMI 206 45.6
Van Vught, 201870 816 ~70e 440 54 Lower GI SMI 412 50.5
Voron, 201571 109 62 ±13 92 84 HPB SMI 59 54.1
Wagner, 201872 424 63 (19–87) 203 48 HPB TPI 145 34.2
Zhuang, 201673 937 64 ± 15 730 78 Upper GI SMI 389 41.5
aMean ± SD, median (range), a: interquartile range.
bHPB: liver, pancreas, bile ducts; Upper GI: esophagus, stomach; Lower GI: colon, rectum, peritoneal carcinomatosis; urogenital: kidney,
prostate, bladder, ovary, endometrium; Other.
cNR: not reported.
dEstimated, based on both included and excluded patients.
eEstimated, calculation based on mean/median age in different groups.
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in this work, the reported value of a low psoas mass as pre-
dictor for the development of postoperative complications
is outperformed by tests incorporating strength and coordi-
nation, i.e. the Timed Up and Go (TUG) (OR: 3.43, 95% CI
1.14–10.35 versus ORpooled: 2.06, 95% CI: 1.37–3.09, respec-
tively).79 A less clear picture is present when the predictive
value of a low psoas mass is compared with the presence of
frailty. Different frailty assessments yield different ORs for
the prediction of postoperative complications, with ORs rang-
ing 1.80–6.40.3,4 The OR for low psoas mass is in the lower
range of this spectrum. This indicates that the value of the
assessment of the psoas mass as a replacement for frailty
screening is limited. Nevertheless, sarcopenia is a cause of
physical frailty, and assessment of sarcopenia might help to
select those patients that are physical frail.80 Therefore, de-
spite the limited value of radiologically assessed sarcopenia
as a stand-alone risk factor, screening on sarcopenia with
use of the psoas mass might be an addition to existing
multi-domain assessments.
An important strength of this meta-analysis is the quality
of the studies used in this analysis. Next to the 17 studies
marked as having a good methodological quality, a total of
25 other studies did perform a multivariate analysis for other
outcomes. With the presence of a multivariate analysis in
itself as an indicator of quality, almost 80% of the studies in-
cluded in this meta-analysis can be considered as having a
good methodological quality. Another strong point is the
fairly high homogeneity in this meta-analysis, thus showing
that the results are consistent across studies and can be used
in the general population of patients with abdominal malig-
nancies. Furthermore, this research showed that there is no
selection bias for patients undergoing surgical treatment for
Figure 2 Sarcopenia and the development of severe postoperative complications
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a malignancy based on ‘eyeballing’ for the presence of
sarcopenia. The number of patients with sarcopenia under-
going oncologic surgery remains relatively stable over the
years. If the selection bias was present, a decrease in the
number of patients with sarcopenia who underwent major
oncological surgery should be expected. This study also has
some limitations. First, all included studies were retrospec-
tive cohort studies, with known disadvantages regarding risk
of bias and potential missing data. Secondly, the used cut-off
values for total skeletal muscle mass and psoas mass in the
studies included in this analysis varied greatly. In the studies
included in this meta-analysis, a total of 37 different cut-off
values, divided in 24 different values for studies using the to-
tal skeletal muscle mass and 13 different values for studies
using the psoas mass, were used, limiting the degree of com-
parability between the outcomes of the different studies.
Furthermore, the number of studies reporting on the psoas
mass is relatively small. However, with over 3000 patients in-
cluded in these studies, the number of included patients is
deemed large enough to reliably determine the differences
between the psoas mass and the total skeletal muscle mass
as a risk factor for postoperative morbidity. Another limita-
tion is the exclusion of studies investigating the influence
of the total skeletal muscle mass as a continuous variable
Figure 3 Predictive value of total skeletal muscle mass and total psoas mass (a) Severe postoperative complications
Sarcopenia and postoperative morbidity in surgical oncology 9
Sarcopenia and postoperative morbidity in surgical oncology 2020
DOI: 10.1002/jcsm.12529
(N=5), without cut-off values to determine sarcopenia, on
the development of sarcopenia. The exclusion of these
studies does lead to missing of data, but evaluation of these
studies showed the same trend in the relationship between
skeletal muscle mass and sarcopenia as was described in this
meta-analysis.
Figure 4 Sarcopenia and 30 day mortality
Figure 3 (b) 30-day mortality
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Based on the results of this meta-analysis, several subjects
for future research arise. An important subject is combining
the radiologically assessed psoas mass with tools assessing
muscle strength and functioning, and possible also including
factors as coordination and cognition. Assessment of the
psoas mass adds quantification of the lean skeletal muscle
mass to the existing information. This might lead to a better
assessment of the patient physical condition and might sub-
sequently further improve preoperative risk stratification.
Furthermore, the position of sarcopenia relative to frailty in
the preoperative risk stratification should be evaluated. As
mentioned, sarcopenia can contribute to frailty, but it does
not equal frailly.80 Therefore, it is not clear whether patients
who are deemed frail are the same patients who are consid-
ered sarcopenic. Research is needed to explore the agree-
ments and differences between those patient groups in
order to determine the place of sarcopenia in future preoper-
ative risk stratification. Another topic is the standardization of
cut-off values for both total psoas mass and total skeletal
muscle mass. As mentioned above, use of standardized cut-
off values improves the comparability between studies. Fur-
thermore, with standardization, it becomes more clear, which
patients are considered sarcopenic and have increased risk of
developing postoperative complications, improving the utility
of radiologically assessed in clinical practice. An entirely other
subject of future research is the preoperative ‘treatment’ of
sarcopenia. Literature showed that resistance training can
be effective to improve muscle strength, skeletal muscle
mass and physical function.81 However, the effects of resis-
tance training on postoperative outcomes is unclear. Further-
more, the benefits of resistance training are not limited to
sarcopenic patients alone but to all elderly, regardless of
whether or not they have sarcopenia,82 which advocates for
the encouragement of physical activity in all elderly, not lim-
ited to those suffering from sarcopenia.
In summary, radiologically assessed preoperative
sarcopenia is associated with the development of postopera-
tive complications. The presence of low psoas mass surpasses
the presence of low skeletal muscle mass as a risk factor for
the development of severe postoperative complications,
and even more so as a risk factor for 30-day mortality, in pa-
tients undergoing surgery for a solid malignancy. The addition
of assessment of the total psoas mass to existing screening
tools focussing on muscle strength and coordination could
lead to further improvement of preoperative risk stratifica-
tion in surgical oncology.
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